Harpoon Therapeutics, Inc. (HARP) Research

Harpoon Therapeutics, Inc. is a clinical-stage biotechnology firm dedicated to immunotherapy, focused on engineering a novel class of T cell activators. These therapies are designed to leverage the body's own immune system to fight cancer and other diseases in patients across the United States. The company's innovative Tri-specific T cell activating construct (TriTAC) platform forms the basis of its development pipeline. This includes HPN328, currently undergoing Phase I/II clinical trials for small cell lung cancer and tumors that express Delta-like canonical Notch ligand 3; HPN217, also in Phase I/II trials for the treatment of multiple myeloma; and HPN536, which is in Phase I/IIa clinical evaluation for ovarian and pancreatic cancers, alongside other mesothelin-expressing tumors. Furthermore, Harpoon has a preclinical asset, HPN601, aimed at various solid tumor indications. The company has also established a discovery collaboration and licensing agreement with AbbVie Biotechnology Ltd. to develop and market products combining its unique TriTAC technology with soluble T cell receptors. Founded in 2015, Harpoon Therapeutics, Inc. is headquartered in South San Francisco, California.

Market snapshot

Symbol
HARP
Price
$23.01
Day change
+0.09%
Market cap
$865.1M
P/E ratio
-1.14x
52-week range
3.11-23.21
Sector
Healthcare
Industry
Biotechnology
Analyst price target
$700

Peer companies

  • Albireo Pharma, Inc. (ALBO)
  • ASLAN Pharmaceuticals Limited (ASLN)
  • Crescent Biopharma, Inc. (CBIO)
  • Avid Bioservices, Inc. (CDMO)
  • Chimerix, Inc. (CMRX)
  • Gracell Biotechnologies Inc. (GRCL)
  • Intercept Pharmaceuticals, Inc. (ICPT)
  • Icosavax, Inc. (ICVX)

Recent insider activity

  • New Leaf Biopharma Opportunities II, L.P. — D-Return (10000 shares) on 2024-03-11
  • New Leaf Biopharma Opportunities II, L.P. — D-Return (299430 shares) on 2024-03-11
  • New Leaf Biopharma Opportunities II, L.P. — D-Return (395783 shares) on 2024-03-11
  • New Leaf Biopharma Opportunities II, L.P. — D-Return (85750 shares) on 2024-03-11
  • SILVERNAIL LAUREN P — D-Return (5000 shares) on 2024-03-11

Open Harpoon Therapeutics, Inc. (HARP) in Thesis for live fundamentals, charts, options context, and portfolio-aware Copilot follow-ups.